Spinifex Pharma names new CMO
This article was originally published in Scrip
Executive Summary
Spinifex Pharmaceuticals, a pain drug development company, has appointed Dr Ronald Marcus chief medical officer – effective immediately. He joins the Melbourne, Australia-based firm from Bristol-Myers Squibb, where he held a number of senior leadership positions within the drugmaker's neuroscience division. At Spinifex Dr Marcus will be responsible for developing the firm's lead candidate, chronic pain drug EMA401, and the company's pre-clinical pipeline.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.